RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has maintained an Outperform rating on Cormedix (NASDAQ:CRMD) and increased the price target from $6 to $10.
November 15, 2023 | 6:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Gregory Renza reaffirmed an Outperform rating on Cormedix and raised the price target from $6 to $10, signaling a positive outlook on the stock.
The increase in price target by a reputable analyst typically indicates a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100